In this issue of Blood, Giles and colleagues report the remarkable clinical activity of MK-0457, an aurora kinase inhibitor, in 3 Philadelphia chromosome-positive leukemia patients harboring the highly resistant T315I mutation.
MK-0457: a light at the end of the tunnel? / Martinelli G.; Soverini S.; Iacobucci I.; Baccarani M.. - In: BLOOD. - ISSN 0006-4971. - STAMPA. - 109:2(2007), pp. 396-397. [10.1182/blood-2006-10-049320]
MK-0457: a light at the end of the tunnel?
MARTINELLI, GIOVANNI;SOVERINI, SIMONA;IACOBUCCI, ILARIA;BACCARANI, MICHELE
2007
Abstract
In this issue of Blood, Giles and colleagues report the remarkable clinical activity of MK-0457, an aurora kinase inhibitor, in 3 Philadelphia chromosome-positive leukemia patients harboring the highly resistant T315I mutation.File in questo prodotto:
Eventuali allegati, non sono esposti
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
